These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18983237)

  • 1. Combination therapy for malignant glioma based on PTEN status.
    Gonzalez J; de Groot J
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1767-79. PubMed ID: 18983237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pten signaling in gliomas.
    Knobbe CB; Merlo A; Reifenberger G
    Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration.
    Dey N; Crosswell HE; De P; Parsons R; Peng Q; Su JD; Durden DL
    Cancer Res; 2008 Mar; 68(6):1862-71. PubMed ID: 18339867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T11TS immunotherapy repairs PI3K-AKT signaling in T-cells: Clues toward enhanced T-cell survival in rat glioma model.
    Chaudhuri S; Singh MK; Bhattacharya D; Datta A; Hazra I; Mondal S; Faruk Sk Md O; Ronsard L; Ghosh TK; Chaudhuri S
    J Cell Physiol; 2018 Feb; 233(2):759-770. PubMed ID: 28608562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy.
    Abounader R
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):235-45. PubMed ID: 19192961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targeting for malignant gliomas (Review).
    Kondo Y; Hollingsworth EF; Kondo S
    Int J Oncol; 2004 May; 24(5):1101-9. PubMed ID: 15067331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in Targeted Therapy for Glioma.
    Lin L; Cai J; Jiang C
    Curr Med Chem; 2017; 24(13):1365-1381. PubMed ID: 28019637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
    Stommel JM; Kimmelman AC; Ying H; Nabioullin R; Ponugoti AH; Wiedemeyer R; Stegh AH; Bradner JE; Ligon KL; Brennan C; Chin L; DePinho RA
    Science; 2007 Oct; 318(5848):287-90. PubMed ID: 17872411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted molecular therapy of malignant gliomas.
    Kesari S; Ramakrishna N; Sauvageot C; Stiles CD; Wen PY
    Curr Neurol Neurosci Rep; 2005 May; 5(3):186-97. PubMed ID: 15865884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.
    Lefranc F; Rynkowski M; DeWitte O; Kiss R
    Adv Tech Stand Neurosurg; 2009; 34():3-35. PubMed ID: 19368079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
    Juratli TA; Schackert G; Krex D
    Pharmacol Ther; 2013 Sep; 139(3):341-58. PubMed ID: 23694764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecularly targeted therapy for malignant glioma.
    Sathornsumetee S; Reardon DA; Desjardins A; Quinn JA; Vredenburgh JJ; Rich JN
    Cancer; 2007 Jul; 110(1):13-24. PubMed ID: 17520692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting malignant glioma survival signalling to improve clinical outcomes.
    Wong ML; Kaye AH; Hovens CM
    J Clin Neurosci; 2007 Apr; 14(4):301-8. PubMed ID: 17276069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors.
    Castellino RC; Durden DL
    Nat Clin Pract Neurol; 2007 Dec; 3(12):682-93. PubMed ID: 18046441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
    Guillamo JS; de Boüard S; Valable S; Marteau L; Leuraud P; Marie Y; Poupon MF; Parienti JJ; Raymond E; Peschanski M
    Clin Cancer Res; 2009 Jun; 15(11):3697-704. PubMed ID: 19435839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment.
    Su JD; Mayo LD; Donner DB; Durden DL
    Cancer Res; 2003 Jul; 63(13):3585-92. PubMed ID: 12839945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
    Coughlin CM; Johnston DS; Strahs A; Burczynski ME; Bacus S; Hill J; Feingold JM; Zacharchuk C; Berkenblit A
    Breast Cancer Res Treat; 2010 Nov; 124(1):1-11. PubMed ID: 20803067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.